iShares S&P Small-Cap 600 Value

Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

After falling around 30% in 2016, Supervalu’s (SVU) stock continues to be in the red in 2017.